Molbio Diagnostics Limited, a pioneer in point-of-care molecular diagnostics, recently unveiled their latest innovation, Truenat HPV-HR Plus, which enables expanded high-risk genotype detection.
The chip-based RT-PCR test allows rapid and decentralized detection of eight high-risk genotypes of human papillomavirus (HPV) – which account for over 96% of cervical cancer cases globally.
The multicentric validation was supported by the Grand Challenges India, Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Biotechnology (DBT), Government of India under its program “Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India”, making it one of the most trusted, indigenously developed tools for cervical cancer screening in India.
India continues to bear a disproportionate burden of cervical cancer, accounting for nearly 25% of global cases. With more than 1,23,000 new diagnoses and around 77,000 deaths each year, the disease remains the second most common cancer among Indian women — despite being preventable through timely screening.
Highlighting the importance of developing homegrown solutions, Rajesh S. Gokhale, Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India said “Truenat HPV-HR Plus represents the kind of diagnostic innovation we need — dependable, scientifically rigorous, locally developed, and built to serve our public health system. It’s a huge step forward in strengthening cervical cancer screening across India.”
Truenat HPV-HR Plus is a simple, fast, and reliable test that checks for high-risk HPV infections using a portable device. Designed to work with cervical swab samples collected by a clinician, it gives highly accurate results in just 60 minutes. Easy to use and with high stability at room temperature, it requires minimal biosafety and is optimized for use at both the lab and near-patient settings.
